Nonalcoholic Fatty Liver / Nonalcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) is an advanced form of fatty liver disease. It is caused by excess fat in the liver that leads to inflammation and tissue injury.
People with type 2 diabetes, obesity, high cholesterol, insulin resistance, and high blood pressure may have NASH.
ACRC Trials is conducting a research study to evaluate an investigational drug for NASH.
|Clinical Study Identifier||TX150235|
|Last Modified on||23 November 2020|
Select a piece of text and start making personal notes.
You have contacted , on
Your message has been sent to the study team at ,
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.Learn more
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.Learn more
Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.Learn more
Congrats! You have your own personal workspace now.